Atara Biotherapeutics, Inc.
- Last sale
- Nov 12, 2026 · -3.72%
- Market cap
- $80.44M
- 10.19M shares
- Filings
- 1,018
Q3 2026−6.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−66.1% FY25 yoy
- $80.44M
- —
- 20.3×
- —
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $120,772,000 | reported | |
| FY 2024 | 2024-12-31 | $128,940,000 | reported | |
| FY 2023 | 2023-12-31 | $8,573,000 | reported | |
| FY 2022 | 2022-12-31 | $63,573,000 | reported |
Biological products, except diagnostic substances
Atara Biotherapeutics, Inc. is the 27th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
RGNXRegenxbio Inc.$170.4M104.5%113.8%$531.0MDNAGinkgo Bioworks Holdings, Inc.$170.2M25.1%183.8%$658.8MBEAMBeam Therapeutics Inc.$139.7M120.0%57.2%$2.5BGLUEMonte Rosa Therapeutics, Inc.$123.7M63.5%31.2%$793.0M
ATRAAtara Biotherapeutics, Inc. (this company)$120.8M6.3%27.1%$80.4M
AGENAgenus Inc$114.2M10.4%2.7%$323.1MIBRXImmunityBio, Inc.$113.3M668.3%310.2%$6.5BIPSCCentury Therapeutics, Inc.$109.2M1,556.8%8.8%$294.2MSTROSutro Biopharma, Inc.$102.5M65.2%186.5%$159.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR